



Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference

September 8, 2022

BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:30 p.m. ET.

The presentation will discuss Aprea's discovery program and development pipeline in synthetic lethality and DDR, including:

- ATRN-119, the Company's Phase 1-ready small molecule ATR inhibitor
- ATRN-W1051, the Company's WEE1 inhibitor in preclinical development
- Repli-Biom, the Company's discovery platform to identify both new precision oncology targets and patient populations most likely to benefit from treatment
- Eprenetapopt, the Company's clinical-stage small molecule p53 reactivator

A copy of the presentation will be accessible from the "Events Calendar" in the News and Events section of the Aprea website.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Doylestown, Pennsylvania, focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways. The Company's lead program is ATRN-119, a Phase 1-ready small molecule ATR inhibitor being developed for solid tumor indications. ATRN-W1051, the Company's novel WEE1 inhibitor, is in preclinical development. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at <https://ir.aprea.com/> as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward Looking Statement

Certain information contained in this press release includes "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as "future," "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "targeting," "confidence," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: Aprea Therapeutics, Inc.

Corporate Contacts:

Scott M. Coiante
Sr. Vice President and Chief Financial Officer
617-463-9385

Gregory A. Korbel
Sr. Vice President and Chief Operating Officer
617-463-9385



Source: Aprea Therapeutics